Thomas Stubig
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Journal: Acta haematologica
Published: January 22, 2015
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Journal: British journal of haematology
Published: November 29, 2014
CD133 marks a stem cell population that drives human primary myelofibrosis.
Journal: Haematologica
Published: October 01, 2014
Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 10, 2014
Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: January 16, 2014
5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.
Journal: Mediators of inflammation
Published: December 06, 2013
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: October 03, 2013
Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: July 27, 2013
CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: May 07, 2013
Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Journal: Annals of hematology
Published: September 07, 2012
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: August 01, 2012
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Journal: Experimental hematology
Published: June 23, 2012
Last Updated: 09/26/2026